343 related articles for article (PubMed ID: 35203256)
21. Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer.
Choi MG; Kim YJ; Lee JC; Rho JK; Choi CM
Thorac Cancer; 2020 Nov; 11(11):3337-3345. PubMed ID: 33017518
[TBL] [Abstract][Full Text] [Related]
22. Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer.
Ge Y; Ye T; Fu S; Jiang X; Song H; Liu B; Wang G; Wang J
Front Immunol; 2023; 14():1114041. PubMed ID: 37153619
[TBL] [Abstract][Full Text] [Related]
23. Infiltration of NK and plasma cells is associated with a distinct immune subset in non-small cell lung cancer.
Backman M; La Fleur L; Kurppa P; Djureinovic D; Elfving H; Brunnström H; Mattsson JSM; Lindberg A; Pontén V; Eltahir M; Mangsbo S; Gulyas M; Isaksson J; Jirström K; Kärre K; Leandersson K; Mezheyeuski A; Pontén F; Strell C; Lindskog C; Botling J; Micke P
J Pathol; 2021 Nov; 255(3):243-256. PubMed ID: 34339045
[TBL] [Abstract][Full Text] [Related]
24. NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors.
Park HR; Ahn YO; Kim TM; Kim S; Kim S; Lee YS; Kim M; Keam B; Kim DW; Heo DS
Cytotherapy; 2019 Jun; 21(6):603-611. PubMed ID: 31010733
[TBL] [Abstract][Full Text] [Related]
25. Tanshinone IIA enhances susceptibility of non-small cell lung cancer cells to NK cell-mediated lysis by up-regulating ULBP1 and DR5.
Sun Y; Gong C; Ni Z; Hu D; Ng W; Zhu X; Wang L; Si G; Yan X; Zhao C; Yao C; Zhu S
J Leukoc Biol; 2021 Aug; 110(2):315-325. PubMed ID: 33909909
[TBL] [Abstract][Full Text] [Related]
26. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
27. Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer.
Al Omar SY; Marshall E; Middleton D; Christmas SE
Immunology; 2011 May; 133(1):94-104. PubMed ID: 21342183
[TBL] [Abstract][Full Text] [Related]
28. Remodeled tumor immune microenvironment (TIME) parade via natural killer cells reprogramming in breast cancer.
Elanany MM; Mostafa D; Hamdy NM
Life Sci; 2023 Oct; 330():121997. PubMed ID: 37536617
[TBL] [Abstract][Full Text] [Related]
29. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
Nersesian S; Glazebrook H; Toulany J; Grantham SR; Boudreau JE
Front Immunol; 2019; 10():1782. PubMed ID: 31456796
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-130a enhances the killing ability of natural killer cells against non-small cell lung cancer cells by targeting signal transducers and activators of transcription 3.
Zhou X; Liu S; Liu J; Zhang Z; Mao X; Zhou H
Biochem Biophys Res Commun; 2020 Mar; 523(2):481-486. PubMed ID: 31883616
[TBL] [Abstract][Full Text] [Related]
31. Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
Popat S; Grohé C; Corral J; Reck M; Novello S; Gottfried M; Radonjic D; Kaiser R
Lung Cancer; 2020 Jun; 144():76-84. PubMed ID: 32387684
[TBL] [Abstract][Full Text] [Related]
32. Radiation and Modulation of the Tumor Immune Microenvironment in Non-Small Cell Lung Cancer.
Goff PH; Zeng J; Rengan R; Schaub SK
Semin Radiat Oncol; 2021 Apr; 31(2):133-139. PubMed ID: 33610270
[TBL] [Abstract][Full Text] [Related]
33. Tissue-resident CD69
Chen X; Chen Y; Xin Z; Lin M; Hao Z; Chen D; He T; Zhao L; Wu D; Wu P; Chai Y
Eur J Immunol; 2022 Dec; 52(12):1993-2005. PubMed ID: 36205624
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of resistance to chemotherapy in non-small cell lung cancer.
Min HY; Lee HY
Arch Pharm Res; 2021 Feb; 44(2):146-164. PubMed ID: 33608812
[TBL] [Abstract][Full Text] [Related]
36. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
[TBL] [Abstract][Full Text] [Related]
37. Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives.
Guo H; Zhang J; Qin C; Yan H; Liu T; Hu H; Tang S; Tang S; Zhou H
Cells; 2022 Oct; 11(20):. PubMed ID: 36291069
[TBL] [Abstract][Full Text] [Related]
38. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Yang YJ; Park JC; Kim HK; Kang JH; Park SY
Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
[TBL] [Abstract][Full Text] [Related]
39. Adoptive cell therapies in thoracic malignancies.
Lasvergnas J; Naigeon M; Chouahnia K; Zelek L; Chaput N; Duchemann B
Cancer Immunol Immunother; 2022 Sep; 71(9):2077-2098. PubMed ID: 35129636
[TBL] [Abstract][Full Text] [Related]
40. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells.
Carrega P; Morandi B; Costa R; Frumento G; Forte G; Altavilla G; Ratto GB; Mingari MC; Moretta L; Ferlazzo G
Cancer; 2008 Feb; 112(4):863-75. PubMed ID: 18203207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
